Markets
Eli Lilly’s Valuation: Blockbuster Drug vs. Top Analyst Picks
Eli Lilly benefits from a blockbuster weight loss drug, yet The Motley Fool Stock Advisor did not include LLY in its top...
#stock analysis 21 articles
Stocks
Coeur Mining Stock Trades 4.9% Below Recent Insider Purchase
Shares of Coeur Mining Inc (CDE) are now available at a 4.9% discount compared to EVP Aoife McGrath's recent $10,763 insider investment,...
Markets
Government Halts Anthropic AI Model, Market Focuses Elsewhere
The government recently shut down Anthropic's powerful Fable 5 AI model due to undisclosed concerns. Despite the significant regulatory action, financial analysts...
Stocks
ESCA Faces Potential Dividend Run Ahead of July Ex-Date
Escalade, Inc. (NASD: ESCA) has triggered a 'Potential Dividend Run Alert' from DividendChannel.com, prompting investors to examine historical patterns ahead of its...
Markets
Micron Technology’s Five-Year Outlook: Sustained Growth from AI Memory Demand
Micron Technology is positioned for significant long-term growth, driven by a persistent memory shortage, particularly in high-bandwidth memory for AI data centers....
Markets
Starbucks or Texas Roadhouse: Which Stock Offers Better 2026 Value?
Investors weigh Starbucks' global scale and turnaround efforts against Texas Roadhouse's robust growth and stronger margins for 2026.
Stocks
High Implied Volatility Grips Alnylam Stock Options
Options traders are signaling potential significant price movement in Alnylam Pharmaceuticals (ALNY) stock, with a specific call option exhibiting unusually high implied...
Markets
Mercado Libre Excluded From Top 10 Stock Picks by Prominent Analyst Team
Mercado Libre, often dubbed the 'Amazon of Latin America,' was notably absent from The Motley Fool Stock Advisor's recent list of 10...
Markets
TopBuild Stock: Expert Ratings and Investment Outlook
Motley Fool analysts weigh in on TopBuild (BLD) stock, offering insights into its potential as an investment opportunity. Expert ratings and market...